What this study is
This study will establish the feasibility and preliminary validity of real-time oxygen delivery index (DO₂i) monitoring using noninvasive hemoglobin (SpHb, Masimo) and minimally invasive cardiac output (FloTrac, Edwards) in cardiac surgery patients.
What's being tested
- SpHb monitor
Intervention · DEVICE
The SpHb monitor is an FDA approved device being used according to its approved indications. No additional invasive procedures, blood draws, or interventions are performed for research purposes.
Study details
- Sponsor
- University of Minnesota
- Conditions
- Cardiac Surgery
- Enrolling
- 150 people
- Starts
- 2026-12-15
- Est. completion
- 2027-08-01
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adults ≥ 18 years undergoing cardiac surgery
- Placement of pulmonary artery catheter with continuous cardiac output (CCO) as part of routine clinical care
- Placement of arterial line with FloTrac as part of routine clinical care
- Availability of ≥ 3 arterial blood gas samples at specified timepoints
You can't join if
- Mechanical circulatory support planned or in use (IABP, Impella, ECMO)
- Patients without BOTH pulmonary artery catheter with CCO and arterial line with FloTrac
- Patients who are Research Opt-Out
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Minnesota
Minneapolis, Minnesota, United States
- Sherilyn Landree · Contact612-282-3705landr184@umn.edu
Study team
Sponsor
University of Minnesota
Study ID ANES-2026-34768
Principal investigator
Benjamin Gorbaty, MD
University of Minnesota
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.